Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization

#307

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.

Aim(s): To determine the prognostic features associated with poorer survival in NET patients undergoing Y90 embolization.

Materials and methods: We performed a retrospective review of 110 patients with metastatic NETs who received Y90 embolization between 2004-2010. Kaplan-Meier methods were used. Biomarker responses were calculated within six months of the procedure. Cox Proportional-Hazard Models were then constructed to control for additional variables.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Soltman S, Amin S, Warner R, Weintraub J, Itzkowitz S,

Keywords: neuroendocrine, tumor, biomarker, embolization,